Advertisement

 

 

Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance.

Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance.
Author Information (click to view)

Bychkov A, Jung CK,


Bychkov A, Jung CK, (click to view)

Bychkov A, Jung CK,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Human pathology 2017 10 2471() 74-83 pii 10.1016/j.humpath.2017.10.015

Abstract

CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. Recently, aberrant CD20 expression has been described in a small series of papillary thyroid carcinomas (PTCs). We aimed to evaluate CD20 immunoexpression and to perform clinicopathologic correlation in a large set of thyroid tumors, including a cohort of high-grade thyroid cancer. A total of 625 cases of thyroid tumor comprised tissue microarrays of 538 PTCs and 47 follicular adenomas, and whole-slide sections of 40 aggressive thyroid carcinomas (10 radioiodine-refractory PTCs and 8 poorly differentiated, 5 anaplastic, and 17 medullary thyroid carcinomas) were immunostained with anti-CD20 monoclonal antibody. BRAFV600E mutation was tested by direct sequencing in 478 cancers. Our study found that a small subset of PTCs (<10%, mainly of classic variant) exhibited aberrant membranous expression of CD20. These tumors displayed less aggressive histological features and had a lower prevalence of BRAFV600E mutation. We also discovered that CD20 expression was maintained in 6%-20% of aggressive thyroid cancers but not observed in follicular adenomas. All CD20-positive tumor cells were negative for CD79a and PAX5. Aberrant expression of CD20 by thyroid cancer cells may present a diagnostic pitfall in cytologic evaluation of thyroid and cervical masses. Residual expression of CD20 in aggressive cancers may offer promise for translational implications, which merits further experimental investigation.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 + six =

[ HIDE/SHOW ]